Latigo Biotherapeutics, Inc. LTGO PHARMA
Company Overview
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
Why Investors Should Care
Generates a return on equity of 47.1%, reflecting efficient use of shareholder capital.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -78.4%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -78.43% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -17.70% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | -15.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)41.49 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 47.1%.
CONS
- Earnings shrank at -78.4% CAGR over 5 years.
- Trading 39.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LTGO Latigo Biotherapeutics, Inc. PHARMA | 15.02 | -7.55 | $995.82M | 0.00% | - | 47.12% | - | -78.43% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 21.51M | 25.75M | 23.44M | 25.81M |
| Operating Income | -21.51M | -25.75M | -23.44M | -25.81M |
| EBITDA | -21.45M | -25.77M | -23.39M | -25.49M |
| Interest Expense | - | 0 | - | 251.00K |
| Pretax Income | -20.95M | -25.84M | -22.96M | -25.80M |
| Tax Provision | - | - | - | - |
| Net Income | -20.95M | -25.84M | -22.96M | -25.80M |
| Diluted EPS | -0.48 | -0.59 | -0.52 | -0.43 |
| R&D Expense | - | 22.92M | - | 21.23M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 63.45M | 110.39M |
| Operating Income | -63.45M | -110.39M |
| EBITDA | -63.21M | -110.14M |
| Interest Expense | - | - |
| Pretax Income | -61.18M | -109.17M |
| Tax Provision | - | - |
| Net Income | -61.18M | -109.17M |
| Diluted EPS | -1.39 | -2.48 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 22.86M | 75.52M |
| Current Assets | 21.16M | 73.83M |
| Cash & Equivalents | 17.92M | 69.44M |
| Inventory | - | - |
| Receivables | - | - |
| Total Liabilities | 152.46M | 307.19M |
| Current Liabilities | 14.44M | 18.45M |
| Long Term Debt | - | - |
| Total Debt | 851.00K | 690.00K |
| Total Equity | -129.60M | -231.67M |
| Shares Outstanding | 60.15M | 60.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -50.95M | -97.56M |
| Investing Cash Flow | -72.00K | -136.00K |
| Financing Cash Flow | 607.00K | 149.50M |
| Capital Expenditure | -72.00K | -136.00K |
| Free Cash Flow | -51.03M | -97.69M |
| Net Change in Cash | -50.42M | 51.80M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 47.2% | 47.1% |
| ROCE % | -752.8% | -193.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LTGO
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE9wSWdmd2sta3BNUGlIamlaVDdOM1ZxbWdYZzFzcWdXdVZnUklMZUI5MjUzMlo2dkZKRnFEOVIzRmNMS3llX3B6blJWNHh6dFI0?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Latigo Biotherapeutics (NASDAQ:LTGO) Shares Down 6.3% - Should You Sell? - MarketBeat
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQbWRhU0RqcU4zeU1pWVM4Q2gwQzdsMXFub3VNQ0p3VFMtazV3WHVZUkdMRTdsU1BqOFhNYmhyQzJIVGJibkI3eVozX2hsMjVaSldZcmNua2E1ZDRNdTdFcFE0RDZaUlp0Z21SRDFxb1dURHJUMmhCWFVjOTNnSnVyRFhsV2F4OXNnZGx6Zm…
Latigo Biotherapeutics, Inc. (LTGO) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE1GcHRoWUZ5TFBOQW9EYUthTWliTVZWMm5XNVd1aDI4aTBMYzdYWXIwdTdQTWFfMjQ2d0pTckp6emstLWFaeHR4dTV4aUtQMGQtVXVORjlkdHctYUJDcm9YWA?oc=5" target="_blank">Latigo Biotherapeutics, Inc. (LTGO) s…
Latigo Biotherapeutics (LTGO) Stock Price, News & Analysis - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTFA3enQtUElwYjRGRGdvZTJyT3Q2RFJMZWJFdTdMRWpud3M5T1ZKdEtTOGdMNW1MeUdjZWdGM2RtUWRpWW1ibldmeVV3Q1hQVWJVejlB?oc=5" target="_blank">Latigo Biotherapeutics (LTGO) Stock Price, News & Analy…
Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It (NASDAQ:LTGO) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOR1c3S29fd3YzR01fVklPTHVLdzhWQnJ3VklwQ0NTeC00aWdLaTJ0V294anllcXN1MUFILWRsTHNIQVgzZFFockNrclJ1VVctUGJrRGtTMy05c2tqeXRfcEhqWGY5V3dHRTdvNjk0WUNjVDVnVUVUOG1QUDlfa3JuWHJGYVFocEZZdlg4M3…
Latigo Biotherapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOMngxbUU5VmFVTHYxSHIxZE83aklsUFltMTMyMVF6ZVpGSTR1RFNLcWFmcGVyalNMM3FJREZBY0ZMMFBTZUtyV1dzVFdMUVVMbXVUWUVCdzh6RUpKeG5nWjNLN0pKWlFsOHZ4OU8yOV8tZ19FMmZkYkg1RENINUtFRGpEanczdGtxNWhkek…
LTGO — Frequently Asked Questions
What is the current share price of Latigo Biotherapeutics, Inc. (LTGO)?
As of 2026-10-23 16:27 PDT, Latigo Biotherapeutics, Inc. (LTGO) trades at $15.02 on NasdaqGS. Its 52-week range is $14.00 to $25.00.
What is the market capitalisation of LTGO?
Latigo Biotherapeutics, Inc. (LTGO) has a market capitalisation of $995.82M on NasdaqGS.
What is the P/E ratio of LTGO?
LTGO trades at a trailing price-to-earnings (P/E) ratio of -7.55. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is -0.06.
What is the return on equity (ROE) of LTGO?
LTGO has a return on equity (ROE) of 47.12%.
Is LTGO a good stock to buy?
This page provides a data-driven analysis of Latigo Biotherapeutics, Inc. (LTGO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.